

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2024

This document is adapted from NIOSH List of Antineoplastics and Other Hazardous Drugs in Healthcare Settings and NIOSH Alert: Preventing Occupational Exposure to Anti-neoplastic and Other Hazardous Drugs in Health Care Settings, 2024 available at <https://www.cdc.gov/niosh/docs/2025-103/default.html> [DHHS (NIOSH) Publication No. 2025-103]. When handling any chemicals listed appropriate safety precautions must be taken to prevent exposure to skin, mucous membranes, lungs and to prevent/limit environmental exposure. Highlighted items are commonly used in community compounding settings.

TABLE 1 contains drugs that have MSHI in the package insert and/or meet the NIOSH definition of a hazardous drug and one or more of these criteria: Are classified by the National Toxicology Program (NTP) as "known to be a human carcinogen" Are classified by the International Agency for Research on Cancer (IARC) as Group 1 "carcinogenic to humans" or Group 2A "probably carcinogenic to humans"

ado-trastuzumab emtansine	enfortumab vedotin	mycophenolate mofetil
altretamine	epirubicin	nelarabine
amsacrine	eribulin mesylate	omacetaxine
arsenic trioxide	estramustine	oxaliplatin
azacitidine	estrogen/ progesterone combinations	paclitaxel
azathioprine	estrogens, conjugated	panobinostat
belantamab mafodotin	estrogens, esterified	pemetrexed
belinostat	etoposide	pentostatin
bendamustine	everolimus	polatuzumab vedotin
bleomycin	fam-trastuzumab deruxtecan	pomalidomide
bortezomib	foxuridine	pralatrexate
brentuximab vedotin	fudarabine	procarbazine
busulfan	ganciclovir	romidepsin
cabazitaxel	gemcitabine	sacituzumab govitecan
capecitabine	gemtuzumab ozogamicin	streptozocin
carboplatin	hydroxyurea	tamoxifen
carmustine	idarubicin	temozolomide
chlorambucil	ifosfamide	temsirolimus
chloramphenicol	imatinib	teniposide
cidofovir	inotuzumab ozogamicin	thalidomide
cisplatin	irinotecan	thioguanine
cladribine	ixabepilone	thiotepa
clofarabine	ixazomib	tisotumab-vedotin
cyclophosphamide	lenalidomide	topotecan
cyclosporine	loncastuximab tesirine	trabectedin
cytarabine	lomustine	trifuridine
dacarbazine	lurbinectedin	uracil mustard
dactinomycin	melfhalan	valganciclovir
dasatinib	melfhalan fufenamide	valrubicin
daunorubicin	mercaptopurine	vandetanib
decitabine	methotrexate	vinblastine
dexrazoxane	mirvetuximab soravtansine	vincristine
diethylstilbestrol	mitomycin	vinorelbine
docetaxel	mitotane	vorinostat
doxorubicin	mitoxantrone	

TABLE 2 meet the NIOSH definition of a hazardous drug, and Do not have MSHI Are not classified by the NTP as "known to be a human carcinogen" Are not classified by the IARC as Group 1 "carcinogenic to humans" or Group 2A "probably carcinogenic to humans"

abacavir	fosphenytoin	pazopanib
abiraterone	fulvestrant	peginesatide
acitretin	ganirelix	pentetate calcium trisodium
afatinib	gonadotropin, chorionic	phenoxybenzamine
alefacept	goserelin	phenytoin
alitretinoin	histrelin	pipobroman
ambrisentan	icatibant	plerixafor
anastrozole	isotretinoin	ponatinib
apomorphine	ivabradine	progesterone
axitinib	dinoprostone	progestins
bexarotene	divalproex	propylthiouracil
bicalutamide	dronedarone	raloxifene
blinatumomab	dutasteride	rasagiline
bosentan	entecavir	regorafenib
bosutinib	enzalutamide	ribavirin
cabergoline	lefunomide	riociguat
clobazam	lenvatinib	sirolimus
clomiphene	letrozole	sonidegib
clonazepam	leuprolide	sorafenib
cobimetinib	lomitapide	spironolactone
colchicine	macitentan	sunitinib
crizotinib	medroxyprogesterone	tacrolimus
dabrafenib	megestrol	temazepam
deferiprone	menotropins	terifunomide
degarelix	methimazole	testosterone
dihydroergotamine	methylegonovine	tofacitinib
cabozantinib	methytestosterone	topiramate
carbamazepine	mifepristone	toremifene
carflzomib	miltefosine	trametinib
ceritinib	mipomersen	tretinoin
cetorelix	misoprostol	triptorelin
choriogonadotropin	mycophenolic acid	ulipristal
erlotinib	nafarelin	urofollitropin
eslicarbazepine	nevirapine	valproate/valproic acid
estradiol	nilotinib	vemurafenib
estropipate	olaparib	vigabatrin
exemestane	ospemifene	vismodegib
exenatide	oxcarbazepine	voriconazole
finasteride	oxytocin	warfarin
fingolimod	palifermin	zidovudine
fuconazole	pamidronate	ziprasidone
fuoxymesterone	paroxetine	ziv-afigercept
futamide	pasireotide	zoledronic acid
		zonisamide